# Transition to Rebif New Formulation

> **NCT00619307** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 117 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Rebif New Formulation + prophylactic Ibuprofen
- **DRUG:** Rebif New Formulation + ibuprofen PRN

## Key facts

- **NCT ID:** NCT00619307
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2014-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00619307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00619307, "Transition to Rebif New Formulation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00619307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*